Overview

An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy of saredutant 100mg or 30mg once daily in combination with paroxetine 20mg once daily compared to saredutant placebo in combination with paroxetine 20mg once daily in patients with major depressive disorder. The study also includes a double-placebo group (saredutant placebo in combination with paroxetine placebo).
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Paroxetine